A new phase in the breast cancer battle?

Published By Datamonitor

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor

Abbott/Millennium: genomics partnership advances

Obesity is a serious public health concern, costing over $100 billion a year in the US alone, and MLN4760 will complement Abbott's metabolic disease program well. It is also the first fruit of a strategic alliance to develop drugs based on genomic research. Such alliances will become increasingly important in the industry over the next few years.

Published By Datamonitor

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor

Aventis: promising early stage results for FGF-1

Published By Datamonitor

Bayer/CuraGen: billion-dollar genomics alliance

Published By Datamonitor

Biotechnology: FDA rule changes could boost generics

The FDA's review of current good manufacturing practice (cGMP) seeks to improve standards of drug manufacture. At the same time, the regulations should reduce confusion over biotech-derived drug products. These changes may open the door to greater use of new manufacturing methods and long term, greater opportunities for biogenerics.

Published By Datamonitor

BMS/Celera: drug discovery to get shorter

Hot on the heels of last month's obesity research deal between Merck and deCODE, BMS and Celera have agreed to team up to develop novel cardiovascular and diabetes drugs. Both partnerships are attempts to accelerate the drug discovery process in cardiovascular diseases - increasingly important as the costs of clinical development continue to rise.

Published By Datamonitor

BMS/Pharmagene: investing in gene expression

Published By Datamonitor